Sign In
Buy EDSA
$6.81
-0.540 (-7.35%)
At Close: Jun 22, 2026
Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results
04:15pm, Wednesday, 14'th May 2025
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disease
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
04:30pm, Monday, 28'th Apr 2025
TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disea
Edesa Biotech Announces Chief Financial Officer Transition
04:15pm, Friday, 04'th Apr 2025
TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disea
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results
04:15pm, Friday, 14'th Feb 2025
TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas
Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
07:00am, Thursday, 13'th Feb 2025
TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therape
Edesa Biotech Reports Fiscal Year 2024 Results
04:30pm, Friday, 13'th Dec 2024
TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas
Edesa Biotech's Founder Makes Strategic Investment in the Company
08:15am, Thursday, 31'st Oct 2024
TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas
Edesa Biotech Announces Upcoming Conference Schedule
08:15am, Monday, 21'st Oct 2024
TORONTO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.
07:38pm, Friday, 13'th Sep 2024
MARKHAM, Ontario, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Dr. Pardeep Nijhawan (“Dr. Nijhawan”) announces that as a result of grants of restricted share units (“RSUs”) of Edesa Biotech, Inc. (“Ed
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results
04:20pm, Friday, 09'th Aug 2024
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS
08:20am, Monday, 24'th Jun 2024
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expecte
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
04:15pm, Friday, 10'th May 2024
TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disease
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
09:00am, Thursday, 11'th Apr 2024
TORONTO, ON / ACCESSWIRE / April 11, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disea
Edesa Biotech to Participate in Upcoming Investor Conferences
09:00am, Tuesday, 02'nd Apr 2024
TORONTO, ON / ACCESSWIRE / April 2, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
04:30pm, Thursday, 21'st Mar 2024
TORONTO, ON / ACCESSWIRE / March 21, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disea
